【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Hepatitis C Therapies
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Hepatitis C Therapies
2.1 A Brief History of Hepatitis C and Treatments
2.1.1 Genotypes
2.1.2 Symptoms: Acute and Chronic Hepatitis C
2.1.3 Diagnosing Hepatitis C: The Asymptomatic Nature
2.1.4 Risk Factors for Hepatitis C
2.2 Incidence and Prevalence Patterns
2.3 Hepatitis C: Treatment and Prevention
2.3.1 Antivirals: Inhibiting Virus Replication
2.3.1.1 Protease Inhibitors
2.3.1.2 Polymerase Inhibitors
2.3.1.3 NS5A Replication Complex Inhibitors
2.3.2 Interferons: Dual Mode of Action
2.3.2.1 Combination Therapy: Treatment with Interferons and Antivirals
2.3.2.2 Interferon-Free Regimens
2.3.3 Hepatitis C and the Need for a Vaccine
3. The World Hepatitis C Therapies Market, 2015-2025
3.1 Hepatitis C Therapies Market, 2013 and 2014
3.2 The Hepatitis C Therapies Market: Revenue Forecast, 2014-2025
3.2.1 Rising Awareness and Screening: Expanding Treatment Population
3.2.2 Generic Competition in the Hepatitis C Therapies Market
3.2.3 Biosimilar Interferons
3.2.4 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
3.3 Oral Antivirals Submarket
3.3.1 Oral Antivirals Submarket: Revenue Forecast, 2014-2025
3.3.2 A Strong Developmental Pipeline to Drive Market Growth
3.3.3 All-Oral Treatments for Hepatitis C: Improving Tolerability
3.4 Interferons Submarket
3.4.1 Standard of Care for Hepatitis C
3.4.2 Drawbacks to Interferon Therapy
3.4.3 Declining Revenues 2008-2013
3.4.4 Interferons Submarket: Revenue Forecast, 2014-2025
3.4.5 Next Generation Interferons: A Potential Advance or Lateral Move?
3.5 Hepatitis C Vaccines Submarket
3.6 Hepatitis C Therapies: Submarket Shares 2013, 2019 and 2025
4. Leading National Hepatitis C Markets, 2015-2025
4.1 Global Prevalence of Hepatitis C, 2013
4.1.1 The Importance of Asia
4.2 Hepatitis C Therapies Market: Regional Breakdown, 2013
4.3 Hepatitis C Therapies Market: Regional Forecast, 2014-2025
4.4 The US
4.4.1 Population Movement and Hepatitis C
4.4.2 The Affordable Care Act and Hepatitis C
4.4.3 Increased Screening towards Target Population
4.4.4 The US Revenue Forecast, 2014-2025
4.5 Leading EU Markets for Hepatitis C Therapies
4.5.1 Regional Prevalence
4.5.2 EU5 Market, 2013
4.5.3 EU5: Revenue Forecasts, 2014-2025
4.5.4 Italy: Revenue Forecast, 2014-2025
4.5.5 Spain: Revenue Forecast, 2014-2025
4.5.6 Germany: Revenue Forecast, 2014-2025
4.5.7 UK: Revenue Forecast, 2014-2025
4.5.8 France: Revenue Forecast, 2014-2025
4.6 Hepatitis C in Asia
4.7 China
4.7.1 Decline in Incidence of Hepatitis C
4.7.2 Rising Middle Class
4.7.3 Hepatitis C Outbreaks
4.7.4 Domestic Drug and Vaccine Development
4.7.5 China: Revenue Forecast, 2014-2025
4.8 Japan
4.8.1 Hepatitis C in Japan
4.8.2 Japan: Revenue Forecast, 2014-2025
4.9 India
4.9.1 Low Awareness Rates
4.9.2 India: Revenue Forecast, 2014-2025
4.10 Russia
4.10.1 Low Treatment Rate and High Drug Costs Limiting Market
4.10.2 Adverse Impact of Western Sanctions on Russian Pharma Market
4.10.3 Russia: Revenue Forecast, 2014-2025
4.11 Brazil
4.11.1Current Disease Prevalence
4.11.2 Brazil: Revenue Forecast, 2014-2025
5. Leading Hepatitis C Therapies, Market Prospects to 2025
5.1 Leading Hepatitis C Therapies, 2014-2025
5.2 Sovaldi (Gilead Sciences)
5.2.1 Recent Revenue Analysis
5.2.2 Gilead Licenses Generic Substitute for Sovaldi for Developing Countries
5.2.3 Sovaldi Revenue Forecast, 2014-2025
5.3 Olysio (Janssen/Medivir)
5.3.1 Recent Revenue Analysis
5.3.2 Combination Regimen of Sovaldi and Olysio
5.3.3 Olysio Revenue Forecast, 2014-2025
5.4 Pegasys (Roche)
5.4.1 Recent Revenue Analysis
5.4.2 Label Expansions and Lifecycle Management Strategies
5.4.3 Pegasys Revenue Forecast, 2014-2025
5.5 Incivek (Vertex/Janssen (J&J)/Mitsubishi Tanabe)
5.5.1 Recent Revenue Analysis
5.5.2 Targeting HCV/HIV Co-Infected Patients
5.5.3 Pipeline Competition May Affect Revenues
5.5.4 Incivek Revenue Forecast, 2014-2025
5.6 PegIntron (Merck & Co.)
5.6.1 Recent Revenue Analysis
5.6.2 Competition from Interferon Biosimilars
5.6.3 Enhancing Drug Life Cycle
5.6.4 PegIntron Revenue Forecast, 2014-2025
5.7 Victrelis (Merck & Co.)
5.7.1 Recent Revenue Analysis
5.7.2 Roche Collaboration
5.7.3 Product Differentiation
5.7.4 Victrelis Revenue Forecast, 2014-2025
5.8 Harvoni (Gilead Sciences)
5.8.1 Gilead-AbbVie Dispute over Ledipasvir/Sofosbuvir Patents
5.8.2Harvoni Revenue Forecast, 2014-2025
5.9 Daklinza (Bristol-Myers Squibb)
5.9.1 Daklinza Revenue Forecast, 2014-2025
5.10 Sunvepra (Bristol-Myers Squibb)
5.10.1 Sunvepra: Synergistic Effect with Daklinza
5.10.2 Sunvepra Revenue Forecast, 2014-2025
6. Hepatitis C Therapies Market: Leading R&D Pipeline Candidates, 2014
6.1 Introduction to Hepatitis C Therapy Candidates
6.2 Protease Inhibitors Pipeline
6.2.1 Vaniprevir (Merck & Co.): Patent Security through 2027
6.2.2 MK-5172 and MK-8742 (Merck & Co.): Phase III
6.2.3 Paritaprevir (formerly ABT-450) (AbbVie): Fast-Tracked into Phase III
6.2.4 Sovaprevir (Achillion Pharmaceuticals): Playing Catch Up
6.2.5 ACH-2684 (Achillion Pharmaceuticals)
6.2.6 Danoprevir (Roche): Testing Out Combination Regimens
6.2.7 Lomibuvir (Vertex Pharmaceuticals)
6.2.8 ABT-493 (AbbVie)
6.2.9 Vedroprevir (Gilead Sciences)
6.2.10 GS-9857 (Gilead Sciences)
6.3 Polymerase Inhibitors Pipeline
6.3.1 ACH-2928 (Achillion Pharmaceuticals)
6.3.2 BMS-791325 (Bristol-Myers Squibb): Phase II
6.3.3 TMC-647055 (Janssen): Phase II
6.3.4 Mercitabine (Roche/Pharmasset): Broad Spectrum Treatment
6.3.5 Setrobuvir (Roche): Non-Nucleoside Inhibitor
6.3.6 VX-135 (Vertex Pharmaceuticals): Interferon- and Ribavirin-Free Regimens
6.3.7 GS-9669 (Gilead Sciences)
6.3.8 PPI-383 (Presidio Pharmaceuticals)
6.4 NS5A Inhibitors Pipeline
6.4.1 ABT-530 (AbbVie)
6.4.2 Samatisvir (Merck & Co.): Acquired from Idenix
6.4.3 GS-5816 (Gilead Sciences)
6.4.4 PPI-668 (Presidio Pharmaceuticals)
6.5 Interferon Pipeline
6.5.1 Locteron (Biolex): Controlled Release Formulation
6.5.2 Peginterferon Lambda-1a (Bristol-Myers Squibb): Improved Side Effects Profile
6.6 Novel Inhibitors
6.6.1 SCY-635 (SCYNEXIS)
6.6.2 Miraversen (Santaris)
6.6.3 GS-9620 (Gilead Sciences)
6.6.4 RG-101 (Regulus Therapeutics)
6.7 Hepatitis C Pipeline Candidates on Hold or Discontinued, 2014
6.7.1 Alisporivir (Novartis/Debiopharm): Advanced Cyclophin Inhibitor
6.7.2 INX-189 (Bristol-Myers Squibb): Cardiovascular Effects May Halt Development
6.7.3 Idenix Developments Terminated: IDX-189 and IDX-19368
6.7.4 Deleobuvir (Boehringer Ingelheim): Development Discontinued
6.7.5 Faldaprevir (Boehringer Ingelheim): Exiting the Hepatitis C Market
6.8 Leading Hepatitis C Vaccine Pipeline Candidates, 2014
6.8.1 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals): Therapeutic Vaccine in Phase II Trials
6.8.2 GI-5005 (GlobeImmune): Yeast-Based Hepatitis C Vaccine
6.8.3 INO-8000 HCV (Inovio Pharmaceuticals): Therapeutic Vaccine in Phase I Trials
6.8.4 Okairos Inc.: Prophylactic and Therapeutic Vaccine Candidates
7. Leading Companies in the Hepatitis C Therapies Market
7.1 Leading Market Players, 2013 and 2014
7.2 Gilead Sciences
7.2.1 Product Overview and Performance. 2013 and 2014
7.2.2 Recent Developments: Gilead Sciences Acquires Pharmasset
7.2.3 Hepatitis Pipeline: Strong and Diverse
7.2.4 Future Outlook: Strongest Pipeline than Any Other Company
7.3 Johnson & Johnson (Janssen Pharmaceuticals)
7.3.1 Product Overview and Performance, 2013 and 2014
7.3.2 Recent Developments: Acquisition of Alios BioPharma
7.3.3 Hepatitis Pipeline
7.3.4 Future Outlook: Combination Regimens with Olysio
7.4 Roche
7.4.1 Product Overview and Performance. 2013 and 2014
7.4.2 Recent Developments: Partnership with Anadys
7.4.3 Hepatitis Pipeline
7.4.4 Future Outlook: Slowing Demand May Affect Market Dominance
7.5 Bristol-Myers Squibb
7.5.1 Product Overview and Performance. 2013 and 2014
7.5.2 Recent Developments: Strengthening Product Pipeline through Acquisitions
7.5.2.1 Bristol-Myers Squibb Acquires Inhibitex
7.5.3 Hepatitis Pipeline: Strong Future Position in Hepatitis C
7.5.4 Future Outlook: Market Set For Intense Competition
7.6 Merck & Co.
7.6.1 Product Overview and Performance. 2013 and 2014
7.6.2 Recent Developments: Merck & Co. Acquires Idenix
7.6.3 Hepatitis Pipeline
7.6.4 Future Outlook: Company Pins Hopes on Launch of Pipeline Therapies
7.7 Leading Hepatitis C Pipeline Companies, 2014
7.7.1 Gilead Sciences
7.7.2 Merck & Co.
7.7.3 AbbVie (Formerly Abbott Laboratories): New Venture into Hepatitis C
7.7.4 Achillion Pharmaceuticals: Next Target for Acquisition
7.7.4.1 Achillion and Gilead
8. Hepatitis C Therapies Market: Industry Trends, 2015-2025
8.1 Strengths and Weaknesses in the Hepatitis C Therapies Market, 2014-2025
8.1.1 Interferon Therapy Has Drawbacks
8.1.2 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
8.2 Opportunities and Threats in the Hepatitis C Therapies Market, 2014-2025
8.2.1 Hepatitis Screening and Diagnosis
8.2.2 Raising Awareness and Overcoming Social Stigma
8.2.3 Personalised Therapy
8.2.4 HIV Co-Infection
8.2.5 Asia
8.3 STEP Analysis of The World Hepatitis C Therapies Market, 2014-2025
8.3.1 Social Development
8.3.1.1 Social Implications in China
8.3.2 Technological Advances
8.3.3 Economic Pressures
8.3.4 Political Issues
8.4 Hepatitis C Vaccines
8.5 Oral Direct-Acting Antivirals
8.5.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors
8.5.2 Combining Protease and Polymerase Inhibitors
8.5.3 The Need for Ribavirin
8.5.4 Twelve-Week Treatment Target
8.6 Pharmaceutical Investment in Hepatitis C
8.6.1 Licensing and Partnering Deals
8.6.2 Acquisitions in Hepatitis C
8.6.3 Other Companies of Note for Hepatitis Treatment Developments
9. Research Interviews
9.1 Expert Interview 1: Authority from a Company in the Industry (Views Provided Anonymously)
9.1.1 The Hepatitis C Therapies Market Landscape
9.1.2 Interferon Therapies
9.1.3 The Future Hepatitis C Therapies Market
9.2 Interview with Susan Simon, President of the Hepatitis C Association
9.2.1 Barriers to Treatment
9.2.2 Changes to Treatment in the Past Decade and Coming Years
9.2.3 Support and Awareness for Hepatitis C
10. Conclusions
10.1 State of The Hepatitis Therapies Market, 2013 and 2014
10.2 Growth in The Hepatitis Therapies Market, 2014-2025
10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
10.2.2 Asia as a Hepatitis C Therapies Market
10.3 Concluding Remarks
【レポート販売概要】
■ タイトル：C型肝炎(Hepatitis C)治療薬の世界市場■ 英文：Hepatitis C Therapies: World Industry, R&D And Market Forecasts 2015-2025
■ 発行日：2014年12月
■ 調査会社：visiongain
■ 商品コード：VGAIN4121902
■ 調査対象地域：グローバル
- コンクリート接着剤の世界市場ABSTRACTAbout Concrete Bonding Agents Concrete is a composite material, which is a mixture of coarse aggregates bonded together with a fluid cement that hardens over time. Bonding agents are used to enhance the joining of individual components of a structure without using mechanical fasteners. These products are used in repair applications such as bonding of fresh concrete, sprayed concrete, cemen …
- 仙骨神経刺激療法（SNS）の世界市場2017-2021About sacral nerve stimulationSacral nerve stimulation (SNS) is a medical electrical stimulation therapy that is used to treat long-term bowel control and bladder control symptoms through the modulation of nerves controlling the lower urinary tract and pelvic floor. Technavio’s analysts forecast the global sacral nerve stimulation market to grow at a CAGR of 4.66% during the period 2017-2021. [Cov …
- データセンター向け精密空調機器の世界市場2015-2019About Data Center Precision Air Conditioners Precision air conditioners are used to control temperature and humidity of data centers. They are reliable and offer round-the-clock service. These units are specifically designed to cool the IT equipment in data centers. A precision air conditioner consists of an indoor and outdoor unit. It supplies cold air through the cold air inlet of data center ra …
- 航空向けサイバーセキュリティソリューションの世界市場：航空会社管理、空港管理、航空交通管理、航空貨物管理About Aviation Cyber Security Cyber threats are internet-based attempts to disrupt or damage IT systems and hack critical information using spyware, malware, and phishing. Cyber security solutions help organizations in the Aviation sector detect, monitor, report, and counter cyber threats while maintaining the confidentiality of IT systems. Aviation cyber security solutions help protect critical d …
- デジタルプリント壁紙の世界市場：電子写真、インクジェットGlobal Digitally Printed Wallpaper Market: About this market Technavio’s digitally printed wallpaper market analysis considers sales from both electrophotography and inkjet technologies. Our analysis also considers the sales of digitally printed wallpaper in APAC, Europe, North America, South America, and MEA. In 2018, the electrophotography segment had a significant market share, and this trend i …
- メシチレンの世界市場Mesitylene (CAS 108-67-8) Market Research Report 2013 presents comprehensive data on mesitylene markets globally and regionally (Europe, Asia, North America etc.) The Mesitylene (CAS 108-67-8) Market Research Report 2013 includes mesitylene description, covers its application areas and related patterns. It overviews mesitylene market, names mesitylene producers and indicates its suppliers. Besides …
- IoTセンサの世界市場：圧力、温度、磁気計、加速度計、回転儀、慣性センサ、画像センサThe IoT sensors market was valued at USD 3.34 Billion in 2015 and is expected to reach USD 38.41 Billion by 2022, at a CAGR of 42.08% between 2016 and 2022. The growth of the market is driven by the factors such as development of cheaper, smarter, and smaller sensors, growing market for smart devices and wearables, need for real-time computing of applications, supportive government initiatives, de …
- ソース・ドレッシングの世界市場2019-2023About this market The emergence of private label brands is one of the positive trends that can influence the growth of the global sauces and dressings market during the forecast period. Private label products are priced lower than mainstream brands, and this makes the former popular options among consumers with tight budgets. Various supermarket chains have come up with their own private label bra …
- 世界の100Gラインカード市場動向（2012-2016）TechNavio's analysts forecast the Global 100G Line Card market to grow at a CAGR of 69.97 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing bandwidth requirement from enterprises and end-users. The market has also been witnessing the increasing demand for cloud computing and cloud-based applications. However, the high pricing of 100G lin …
- 超伝導体の世界市場：低温超伝導（LTS）、高温超伝導（HTS）About Superconductors Superconductors are materials that allow the passage of electricity with zero resistance at their critical temperature (Tc). Due to zero resistance, there is no loss of energy in the form of heat or sound. A superconductor is not affected by external magnetic fields when in its superconducting state due to the Meissner effect, which is a unique property exhibited by them. The …
- ホルモン補充療法（HRT）の世界市場：エストロゲン補充療法、成長ホルモン補充療法[Global Hormone Replacement Therapy Market 2015-2019] Covering: An in-depth study of the global hormone replacement therapy market and segmentation by type of hormonal therapy (estrogen replacement therapy and growth hormone replacement therapy), by route of administration (oral, parenteral, and transdermal), and by geography (the Americas, EMEA, and APAC). The report also presents the vendor land …
- 泡ガラスの世界市場予測（～2024年）“Superior fire-proof and insulation properties of foam glass are expected to drive the global foam glass market during the forecast period.” The foam glass market is estimated at 1,503 kilotons in 2019 and is projected to reach 1,964 kilotons by 2024, at a CAGR of 5.5% between 2019 and 2024. Foam glass exhibits good fire resistance, water resistance, corrosion resistance, and is lightweight and bi …
- 液体炭酸の世界市場2015Liquid Carbon Dioxide (CAS 124-38-9) Market Research Report 2015 aims at providing comprehensive data on Liquid Carbon Dioxide market globally and regionally (Europe, Asia, North America, Latin America etc.) The report includes Liquid Carbon Dioxide description, covers its application areas, manufacturing methods, patterns. It captures Liquid Carbon Dioxide market trends, pays close attention to L …
- インドの指絞認証（バイオメトリック）市場Increasing security concerns & issues, data thefts, government programs and need for advanced security systems have boosted the market for biometrics devices in India. India is one of the fastest growing biometrics markets of the world, where majority of the market revenues are generated by government, travel & transportation application. In India’s biometrics market, fingerprint biometrics techno …
- 世界のデジタルコンテンツ市場動向（2012-2016）TechNavio's analysts forecast the Global Digital Content market to grow at a CAGR of 11.71 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing numbers of smartphones and tablets. The Global Digital Content market has also been witnessing an increase in the adoption of cloud services. However, the growing privacy concerns could pose a challeng …
